Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Price to Book Ratio (P/B) on January 14, 2025

Inozyme Pharma, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Inozyme Pharma, Inc. 52-week high Price to Book Ratio (P/B) is 3.77 on March 28, 2024, which is NA below the current Price to Book Ratio (P/B).
Inozyme Pharma, Inc. 52-week low Price to Book Ratio (P/B) is 2.04 on January 16, 2024, which is NA below the current Price to Book Ratio (P/B).
Inozyme Pharma, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 2.79.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO	Dr. Douglas A. Treco Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Summer Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years